CancerDrs

Ovarian Cancer clinical trials in Texas

137 actively recruiting ovarian cancer trials at 36 sites across Texas.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Texas:
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
  • UTMB Health Angleton Danbury Campus — Angleton, Texas
  • Houston Methodist San Jacinto Hospital — Baytown, Texas
  • UT MD Anderson - The Woodlands — Conroe, Texas
  • Houston Methodist Cypress Hospital — Cypress, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Texas:
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
  • Houston Methodist Hospital — Houston, Texas
  • Memorial Hermann Texas Medical Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Texas:
  • Texas Tech University Health Sciences Center-Amarillo — Amarillo, Texas
  • The Don and Sybil Harrington Cancer Center — Amarillo, Texas
  • Dell Children's Medical Center of Central Texas — Austin, Texas
  • Saint Joseph Regional Cancer Center — Bryan, Texas
  • Driscoll Children's Hospital — Corpus Christi, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of s…

Sponsor: Children's Oncology Group
NCT ID: NCT06513962
Sites in Texas:
  • Medical City Dallas Hospital — Dallas, Texas
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • El Paso Children's Hospital — El Paso, Texas
  • Cook Children's Medical Center — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…

Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Texas:
  • USO-Texas Oncology-Central/South Texas — Austin, Texas
  • UT Southwestern Medical Center — Dallas, Texas
  • US Oncology — The Woodlands, Texas
  • USO - Texas Oncology Gulf Coast — Webster, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Texas:
  • Texas Oncology-Abilene — Abilene, Texas
  • Texas Oncology Cancer Center — Austin, Texas
  • Jps Health Network — Fort Worth, Texas
  • The University of Texas Health Science Center Houston — Houston, Texas
  • The University of Texas-Md Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Texas:
  • Texas Oncology-Bedford — Bedford, Texas
  • Houston Area Locations- Woodlands — Conroe, Texas
  • Texas Oncology-Presbyterian Cancer Center Dallas — Dallas, Texas
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • Texas Oncology Paris — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…

Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in Texas:
  • Research Site — San Antonio, Texas
  • Research Site — Tyler, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Texas:
  • Texas Oncology Central — Austin, Texas
  • Texas Oncology-Fort Worth Cancer Center — Fort Worth, Texas
  • Houston Methodist — Houston, Texas
  • MD Anderson Cancer Center — Houston, Texas
  • Texas Oncology — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed o…

Sponsor: AstraZeneca
NCT ID: NCT07816666
Sites in Texas:
  • Research Site — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Texas:
  • Lyndon Baines Johnson General — Houston, Texas
  • Houston Methodist — Houston, Texas
  • M D Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07776691
Sites in Texas:
  • Texas Oncology - DFW ( Site 8005) — Fort Worth, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Texas:
  • Hendrick Medical Center — Abilene, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • Lyndon Baines Johnson General Hospital — Houston, Texas
  • Houston Methodist Hospital — Houston, Texas
  • UT MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05112601
Sites in Texas:
  • Parkland Memorial Hospital — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
  • UT Southwestern/Simmons Cancer Center-Fort Worth — Fort Worth, Texas
  • UT Southwestern Clinical Center at Richardson/Plano — Richardson, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Texas:
  • Site 0103 - University of Texas MD Anderson Cancer Center — Houston, Texas
  • Site 0203 - Texas Oncology — Tyler, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Texas:
  • Texas Oncology - Central/South Texas — Austin, Texas
  • Mary Crowley Cancer Research — Dallas, Texas
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • Texas Oncology - Northeast Texas — Flower Mound, Texas
  • Oncology Consultants — Houston, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Texas:
  • Texas Oncology-Austin Center — Austin, Texas
  • Texas Oncology-San Antonio Medical Center Pharmacy — San Antonio, Texas
  • Texas Oncology-Tyler — Tyler, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Texas:
  • USOR Texas Oncology — Abilene, Texas
  • Texas Oncology - Central / South Texas — Austin, Texas
  • Mary Crowley Cancer Research — Dallas, Texas
  • USOR Texas Oncology — Fort Worth, Texas
  • Texas Oncology - Northeast TX — Tyler, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Texas:
  • New Experimental Therapeutics - NEXT Oncology — Austin, Texas
  • Texas Oncology — Bedford, Texas
  • UT Southwest Simmons Cancer Center — Dallas, Texas
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
  • New Experimental Therapeutics of San Antonio - NEXT Oncology — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …

Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Texas:
  • Texas Oncology - Abilene - Antilley Road /ID# 277739 — Abilene, Texas
  • University of Texas - Southwestern Medical Center /ID# 278289 — Dallas, Texas
  • Texas Oncology - Fort Worth Cancer Center /ID# 277989 — Fort Worth, Texas
  • Texas Oncology - San Antonio Medical Center - Research Drive /ID# 277735 — San Antonio, Texas
  • Texas Oncology - The Woodlands /ID# 277926 — The Woodlands, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Texas:
  • Mary Crowley Cancer Research Center — Dallas, Texas
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center — Dallas, Texas
  • University of Texas Southwestern — Dallas, Texas
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • START San Antonio — San Antonio, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …

Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Texas:
  • The University of Texas MD Anderson Cancer Center — Houston, Texas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Texas:
  • Mary Crowley Cancer Research — Dallas, Texas
  • MD Anderson — Houston, Texas
  • NEXT Dallas — Irving, Texas
  • NEXT Oncology San Antonio — San Antonio, Texas
  • START Texas — San Antonio, Texas
View on ClinicalTrials.gov →

Showing 25 of 137 trials with sites in Texas. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19